Protection Against Rabies Virus by a Bacterium‐Like Particle–Based Subunit Vaccine Displaying the Glycoprotein
Microbial Biotechnology · 2026-11 · 19 (11)
DOI: 10.1111/1751-7915.70494 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, online erschienen am 20.11.2026. Verfasst von Haiyang Cong und 9 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Rabies is a fatal zoonotic disease caused by the rabies virus (RABV) and remains a major global public health concern. Although currently available rabies vaccines provide reliable protection, their widespread application is limited by complicated immunization schedules and relatively high production costs. Therefore, the development of safe, effective and economically accessible next‐generation vaccines is urgently needed. In this study, we developed a novel rabies subunit vaccine based on a bacterium‐like particles (BLPs) delivery platform. Recombinant RABV glycoprotein fused with a peptidoglycan anchor protein (G‐PA) was expressed in insect cells using the baculovirus expression system and successfully displayed on the surface of BLPs, generating the G‐BLPs vaccine candidate. Surface localization of the recombinant G protein was confirmed by transmission electron microscopy and western blot analysis. Immunization in mice demonstrated that both G‐BLPs and adjuvant‐formulated G‐BLPs (Adj‐G‐BLPs) induced high titers of virus‐neutralizing antibodies, reaching 13.25 IU/mL and 27.25 IU/mL, respectively, together with enhanced T‐cell cytokine responses. Transcriptomic profiling further revealed significant enrichment of the IL‐17 signalling pathway and marked upregulation of Ccl2 , indicating activation of multiple immune‐related pathways. Both G‐BLPs and Adj‐G‐BLPs provided complete protection against RABV CVS‐24 challenge and significantly reduced viral loads in brain tissues. These findings demonstrate that the BLP‐based platform can effectively display the RABV glycoprotein and induce both humoral and cellular immune responses, offering a promising and potentially scalable strategy for the development of next‐generation rabies vaccines.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Cong, H., Li, J., Li, J., Chen, Y., Zu, X., Zhang, Y., Yan, F., Xia, X., Wang, J., & Feng, N. (2026). Protection Against Rabies Virus by a Bacterium‐Like Particle–Based Subunit Vaccine Displaying the Glycoprotein. Microbial Biotechnology, 19(11). https://doi.org/10.1111/1751-7915.70494
Vancouver
Cong H, Li J, Li J, Chen Y, Zu X, Zhang Y, et al. Protection Against Rabies Virus by a Bacterium‐Like Particle–Based Subunit Vaccine Displaying the Glycoprotein. Microbial Biotechnology. 2026;19(11). doi:10.1111/1751-7915.70494
BibTeX
@article{Cong2026,
author = {Cong, Haiyang and Li, Jinman and Li, Jiaqi and Chen, Yangyi and Zu, Xuan and Zhang, Yu and Yan, Feihu and Xia, Xianzhu and Wang, Jianzhong and Feng, Na},
title = {Protection Against Rabies Virus by a Bacterium‐Like Particle–Based Subunit Vaccine Displaying the Glycoprotein},
journal = {Microbial Biotechnology},
year = {2026},
volume = {19},
number = {11},
doi = {10.1111/1751-7915.70494}
}
EUVIMED